Alicia M. Cole

Alicia M. Cole

Auto-generated profile, based on publicly available information

Alicia M. Cole

Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2021 in Science
Verified
Journal Article
Closed access
PDF file
DDDiwakar Davar
Diwakar Davar
ADAmiran K. Dzutsev
Amiran K. Dzutsev
JMJohn A. McCulloch
John A. McCulloch
RRRichard R. Rodrigues
Richard R. Rodrigues
JCJoe-Marc Chauvin
Joe-Marc Chauvin
HZHassane M. Zarour
Hassane M. Zarour
New fecal microbiota for cancer patients: The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruch et al. and Davar et al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8 + T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients. Science , this issue p. 602 , p. 595 ; see also p. 573

28 February 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JMJohn A. McCulloch
John A. McCulloch
DDDiwakar Davar
Diwakar Davar
RRRichard R. Rodrigues
Richard R. Rodrigues
JBJonathan H. Badger
Jonathan H. Badger
JFJennifer R. Fang
Jennifer R. Fang
ADAmiran K. Dzutsev
Amiran K. Dzutsev

17 October 2022 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
MFMiriam R. Fernandes
Miriam R. Fernandes
PAPoonam Aggarwal
Poonam Aggarwal
RCRaquel G. F. Costa
Raquel G. F. Costa
ACAlicia M. Cole
Alicia M. Cole
GTGiorgio Trinchieri
Giorgio Trinchieri

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
AHAlexandra R Hyler
Alexandra R Hyler
ACAlicia M. Cole
Alicia M. Cole
RBRidi Barua
Ridi Barua
ADAmiran K. Dzutsev
Amiran K. Dzutsev
ESEva Schmelz
Eva Schmelz
Single-cell level investigations such as DNA and RNA sequencing, protein analyses, and phenotypic studies require an input sample with a high rate of viability (>90%). If too many dead cells are present in the input, degraded proteins and ambient DNA or RNA can increase background noise that may lead to missing identification of crucial targets. Since the cost for single-cell sequencing experiments still remains high, it is critical to ensure the input sample is optimized for high viability to ensure cost-effective and reproducible data. Current bead assays or other sample viability enrichment techniques used in preparation for single-cell analyses typically result in a significant sample loss, sometimes sacrificing 80% of the starting sample, and these preparation steps require multiple passes (> 45 minutes time) and costly kits. These beads or kits can be biased and change the cell population, subject cells to unwanted stresses, and diminish sample integrity with the time needed for preparations. Here, we investigate sample cell viability enrichment on the Cyto R1 Platform, a label-free, cell enrichment, sorting, and recovery platform. At the core, the Cyto R1 uses Cyto Chips, microfluidic technologies with electrical fields, to phenotypically enrich and sort various cells based upon cells’ unique physical structures and subcellular features. Thus, the Cyto R1 ensures native cell recovery without any unwanted cell tagging to maximize sample integrity. In this work, a variety of single cell solutions derived from T cell lymphoma tumors, ascites fluid, and organ tissues were enriched for viable cells to obtain a final sample viability over 90%. Additionally, we aimed to achieve a minimum of 50,000 viable cells, a common target for single-cell sequencing, in as rapid a timeframe as possible. In one sample origin tested, murine T cell lymphomas, the average starting viability was 65 ± 6.5%, and the final viability after enrichment on the Cyto R1 Platform was 95.8 ± 1.8%. Similarly, murine ascites cell mixtures were enriched from average viabilities below 55% up to 91.6 ± 4.2%. For all samples tested, >50,000 viable cells were obtained in under 30 minutes. This work demonstrates that the Cyto R1 can effectively and efficiently enrich a variety of starting samples for high viability (>90%) as required for downstream assays and single-cell sequencing. Citation Format: Alexandra R. Hyler, Alicia M. Cole, Ridi Barua, Amiran K. Dzutsev, Eva M. Schmelz. Cyto R1 Platform enriches samples’ viability for single-cell sequencing and downstream assays [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1687.